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Three common LPL variants, PvuII, HindIII, and the
S447X, have been reported to be associated with plasma lipid
levels and CAD[1,2], although not without some inconsis-
tencies [3,4]. Many association studies had evaluated the
effects of these polymorphisms either separately or in
combination using haplotype analysis [5,6]. To our knowl-
edge, none had examined their combined effects on CAD risk
in the Asian population. In this study, we investigated the
combined impact of the three polymorphisms on CAD
susceptibility in the Chinese and Asian Indians residing in
Singapore who have contrasting CAD risks [7].
Our subjects, all males, comprised 1201 CAD patients
(899 Chinese; 302 Indians) and 841 healthy controls (538
Chinese; 305 Indians). All CAD patients had N50% stenosis
in at least one major coronary arteries as confirmed by
angiography. The healthy controls were random individuals
without any related diseases.
The HindIII/H- and 447X alleles were associated with
decreased CAD risk in the Chinese (Age-adjusted odds ratio,
OR=0.74, 0.50; p=0.0025, 0.001, respectively) and Indians
(OR=0.68, 0.51; p=0.0014, 0.008, respectively). The PvuII/
P- allele was significantly associated with decreased CAD
susceptibility in the Indians (OR=0.76, p=0.049) although it
is paradoxically associated with elevated plasma HDL-
cholesterol (p=0.003) in Chinese. Moreover, the protective
allele frequencies of all three polymorphisms were signifi-
cantly higher in the Indians than in the Chinese. This may
appear counter-intuitive since the mortality rate in the Indians
is three times higher than the Chinese in Singapore [7].
However, given that CAD is a multifactorial disease withmore
than two hundred candidate genes involved, and that LPL is
both anti- and pro-atherosclerotic [8], we do not expect that
therewill always be a consistent correlation between frequency
of a ‘protective’ allele and disease prevalence. Despite having a
higher proportion of the population carrying the ‘protective’
allele in the LPL gene, other genes and environmental factors
might have led to a greater proportion of the Indian individuals
being susceptible to CAD compared to that of the Chinese.
No significant association of the LPL polymorphisms was
found with history of MI and with CAD severity despite
showing significant association with CAD susceptibility. The
underlying mechanisms of atherosclerosis development, MI
occurrence and CAD severity are not the same. Therefore, a
significant association of a LPL allele with CAD would not
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necessary imply a similar relationship with the other two
phenotypes.
The most predominant haplotype, P+H+S, constituting
more than 50% of the population, was significantly and con-
sistently elevated in the CAD patients in both Chinese
(OR=1.33, p=0.0096) and Indians (OR=1.65, p=0.0011).
The S447X polymorphism results in a premature
termination of LPL protein, which has been shown to be of
cardiovascular benefit through increased enzymatic activity
and LDL removal [9]. Although HindIII is within an intronic
region, it could affect the binding of a transcriptional factor
and the LPL expression [10]. P+H+S was consistently
associated with atherogenicity in Chinese and Indians, while
P-H-X and P+H-S were associated with lowered CAD risk in
the Chinese and similarly, P-H-S in Indians. The opposite
effect of P+H+S and P+H-S on CAD susceptibility in the
Chinese also suggests that HindIII may be an independent
functional site, as shown recently [10].
In conclusion, the most prevalent haplotype, P+H+S, was
consistently associated with increased CAD risk in male
Chinese and Indians living in Singapore. Each of the three
individual polymorphisms was associated with CAD risk in
male Chinese and/or Indians, which is not mediated through
their effect on lipid profile.
The authors of this manuscript have certified that they
comply with the Principles of Ethical Publishing in the
International Journal of Cardiology [11].
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We read with a great interest the review of Ntusi and
Mayosi making a point on aetiologies and risk factors of
peripartum cardiomyopathy (PPCM) [1].
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